Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy

Abstract Background Salivary gland function decreases after radiation doses of 39 Gy or higher. Currently, submandibular glands are not routinely spared. We implemented a technique for sparing contralateral submandibular glands (CLSM) during contralateral elective neck irradiation without compromising PTV coverage. Methods Volumetric modulated arc therapy (RapidArc™) plans were applied in 31 patients with stage II-IV HNC without contralateral neck metastases, all of whom received elective treatment to contralateral nodal levels II-IV. Group 1 consisted of 21 patients undergoing concurrent chemo-radiotherapy, with elective nodal doses of 57.75 Gy (PTVelect) and 70 Gy to tumor and pathological nodes (PTVboost) in 7 weeks. Group 2 consisted of 10 patients treated with radiotherapy to 54.45 Gy to PTVelect and 70 Gy to PTVboost in 6 weeks. All clinical plans spared the CLSM using individually adapted constraints. For each patient, a second plan was retrospectively generated without CLSM constraints ('non-sparing plan'). Results PTV coverage was similar for both plans, with 98.7% of PTVelect and 99.2% of PTVboost receiving ≥95% of the prescription dose. The mean CLSM dose in group 1 was 33.2 Gy for clinical plans, versus 50.6 Gy in 'non-sparing plans' (p Conclusions Elective radiotherapy to contralateral nodal levels II-IV using RapidArc consistently limited CLSM doses well below 39 Gy, without compromising PTV-coverage. Future studies will reveal if this extent of dose reduction can reduce patient symptoms.</p

Analysis of components of variance determining probability of setup errors in CBCT-guided stereotactic radiotherapy of lung tumors

PURPOSE: Online tumor matching for SABR lung setup requires margins for inaccuracies due to intra-fraction variability of breathing-averaged tumor position (BATP) and CBCT image guidance. We studied intra-fraction variability during SABR delivery using VMAT, corrected these for measurement inaccuracies, and quantified the CBCT image-guidance uncertainties. MATERIALS AND METHODS: For 193 fractions in 38 patients positioned without immobilization devices, CBCT scans were acquired before and after 2 arcs of a RapidArc treatment. A hidden marker test was performed to determine the accuracy of the CBCT system and an inter-observer test was performed to measure registration accuracy. Intra-fraction variability was calculated after correction for these components of variance, and the prediction interval for setup inaccuracies was determined. RESULTS: Correction for measurement inaccuracies reduced the intra-fraction variability of the BATP from 1.9 to 1.6 mm in AP, from 1.7 to 1.4 mm in SI and from 1.5 to 1.1 mm in LR direction (1 SD). Intra-fraction variability in bony anatomy after correction was ≤ 1 mm (1 SD). The 95% prediction interval to account for CBCT image-guidance uncertainties and intra-fraction variability was determined, and was found to be within our institutional PTV margins of 5 mm. CONCLUSIONS: Our findings show that it is essential to account for measurement and system inaccuracies when obtaining data for validating PTV margins from online CBCT image guidance

Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5 cm

Purpose: Stereotactic ablative body radiation therapy (SABR) for lung tumors ≥5 cm can be associated with more toxicity than that for smaller tumors. We investigated the relationship between dosimetry and toxicity and used a knowledge-based planning solution to retrospectively perform individualized treatment plan quality assurance (QA) with the aim of identifying where planning could have been improved. Methods and Materials: Previous retrospective analysis of 53 patients with primary or recurrent non-small cell lung cancer ≥5 cm, treated with 5- or 8-fraction volumetric modulated arc therapy SABR between 2008 and 2014, showed 30% with grade ≥3 toxicity. During this period, several improvements were made to departmental planning protocols. RapidPlan was used to compare dosimetry of patients with or without grade ≥3 toxicity. A model comprising plans from patients without toxicity and compliant with the current planning protocol was used to provide QA for the plans from patients who had toxicity. Results: Sixteen of 53 patients had grade ≥3 toxicity, including 10 with radiation pneumonitis (RP), 3 with lung hemorrhage (1 of these also had RP), and 1 with airway stenosis/atelectasis. RP was again shown to be significantly correlated with contralateral and total-lung V5 and mean lung dose. The 4 highest contralateral-lung doses belonged to patients with RP. Five of 10 clinical plans in patients with RP had a contralateral-lung mean dose up to 2.5 times higher than that of the knowledge-based plan. For 2 of 3 patients with lung hemorrhage and 1 with airway stenosis/atelectasis, the clinical plans had the highest proximal bronchial tree doses, which was also higher than in plans from the model. In 8 patients with grade ≥3 toxicity, clinical plans had dosimetry similar to that in the predictions from the model. Conclusions: A “no-toxicity” RapidPlan model identified the potential for dosimetric improvement in nearly 50% of historical treatment plans from patients with grade ≥3 toxicity after SABR for lung tumors ≥5 cm. Model-based QA may be useful for benchmarking treatment planning protocols in routine practice and in clinical studies